Helix Acquisition Corp. II - Ordinary Shares - Class A
HLXB
Get informed when a big investor buys or sells
+ FollowMarket Cap$792.53M
Close$
Share Statistics
| Market cap | $792.53 Million |
|---|---|
| Enterprise Value | $740.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.3 |
| Beta | -0.19 |
| Outstanding Shares | 80,054,000 |
Return
| Return on Equity | -72.12% |
|---|---|
| Return on Assets | -61.86% |
| Return on Invested Capital | -61.33% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | -0.2 |
| Price to Sales | - |
| Price to Book Ratio | 2.48 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.72 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 71.11%▼ 16.09% |
|---|---|
| Total Invested | $177.60M▼ 4.67% |
| Investors Holding | 34▲ 2.00% |
ESG Score
No data
About Helix Acquisition Corp. II
88 employees
CEO: Pedro J. Beltran BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the Unit...